New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2012
05:46 EDTPFEBiocon, Pfizer end commercialization agreement
Biocon and Pfizer announced the conclusion of their alliance to commercialize Bioconís biosimilar versions of Insulin and Insulin analog products. The companies have agreed that due to the individual priorities for their respective biosimilars businesses, it is in their best interest to move forward independently.
News For PFE From The Last 14 Days
Check below for free stories on PFE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent PFE news | >>
July 30, 2014
08:01 EDTPFEPfizer enters into agreement to acquire Baxter's portfolio of marketed vaccines
Subscribe for More Information
July 29, 2014
12:13 EDTPFEOn The Fly: Midday Wrap
Subscribe for More Information
10:31 EDTPFEPfizer says looking at 'wide spectrum' of M&A transactions
Sees repurchasing 100M more shares this year.
10:20 EDTPFEPfizer says will look at all deals 'regardless of size'
Subscribe for More Information
08:50 EDTPFEHarris & Harris invests in Accelerator Corporation
Subscribe for More Information
07:12 EDTPFEPfizer reports Q2 GEP revenue $6.51B, GIP revenue $3.55B
Subscribe for More Information
07:09 EDTPFEBristol-Myers, Pfizer granted EU approval for Eliquis for treatment of DVT, PE
Subscribe for More Information
07:06 EDTPFEPfizer sees completing palbociclib filing in advanced breast cancer in August
Subscribe for More Information
07:04 EDTPFEPfizer still sees buying back about $5B in stock this year
Subscribe for More Information
07:03 EDTPFEPfizer backs FY14 adjusted EPS view $2.20-$2.30, consensus $2.24
Lowers FY14 adjusted revenue view to $48.7B-$50.7B from $49.2B-$51.2B previously. The expected negative impact from anticipated multi-source generic competition for Celebrex in the U.S. beginning in December. In addition to the approximate one month of multi-source generic competition, Celebrex revenues also are expected to be negatively impacted in fourth-quarter 2014 by associated wholesaler and retailer destocking.
07:01 EDTPFEPfizer reports Q2 adjusted EPS 58c, consensus 57c
Reports Q2 revenue $12.8B, consensus $12.46B.
July 28, 2014
15:47 EDTPFENotable companies reporting before tomorrow's open
Subscribe for More Information
13:12 EDTPFEEarnings Preview: Pfizer looks for earnings boost from Lyrica, Xalkori
Subscribe for More Information
10:02 EDTPFEOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AcelRx (ACRX) downgraded to Hold from Buy at Canaccord... Anglo American (AAUKY) downgraded to Neutral from Buy at UBS... Aon plc (AON) downgraded to Hold from Buy at Sandler ONeill... Cabot Oil & Gas (COG) downgraded at Oppenheimer... Cisco (CSCO) downgraded to Sector Perform from Outperform at Pacific Crest... Coeur Mining (CDE) downgraded to Market Perform from Outperform at Raymond James... DSW (DSW) downgraded at Sterne Agee... DuPont Fabros (DFT) downgraded to Neutral from Buy at Citigroup... El Paso Electric (EE) downgraded to Hold from Buy at Jefferies... Enphase Energy (ENPH) downgraded to Hold from Buy at Deutsche Bank... GlaxoSmithKline (GSK) downgraded to Neutral from Buy at BofA/Merrill... Horizon Technology (HRZN) downgraded to Hold from Buy at Wunderlich... Lear (LEA) downgraded to Hold from Buy at Deutsche Bank... Life Time Fitness (LTM) downgraded at Wedbush... Monster Beverage (MNST) downgraded to Neutral from Buy at UBS... NRG Energy (NRG) downgraded to Buy from Conviction Buy at Goldman... PG&E (PCG) downgraded to Sell from Neutral at Goldman... Pfizer (PFE) downgraded at BMO Capital... Post Properties (PPS) downgraded to Neutral from Buy at Citigroup... Publicis (PUBGY) downgraded to Sell from Neutral at Citigroup... Selmer Scientific (SMLR) downgraded to Hold from Buy at Aegis... TransCanada (TRP) downgraded to Neutral from Outperform at Credit Suisse... Travelers (TRV) downgraded to Hold from Buy at Sandler O'Neill... Zurich Insurance (ZURVY) downgraded to Underperform from Market Perform at Bernstein.
08:43 EDTPFEPfizer downgraded at BMO Capital
As noted earlier, BMO Capital downgraded Pfizer to Market Perform from Outperform. As reasons for the downgrade, the firm cited what it sees as the weakening of the company's mature franchises and significant loss of exclusivity headwinds in 2015. Target to $31 from $34.
06:36 EDTPFEPfizer downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
05:55 EDTPFEStocks with implied volatility movement; IGT PFE
Subscribe for More Information
July 25, 2014
07:29 EDTPFEEMA recommends indication for Ecalta to treat invasive candidiasis
The Committee for Medicinal Products for Human Use adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product Ecalta, offered by Pfizer. The CHMP adopted a change to an indication as follows: "Treatment of invasive candidiasis in adult patients."
July 22, 2014
16:18 EDTPFEPuma Biotech now responsible for R&D expenses associated with legacy trials
Subscribe for More Information
July 17, 2014
08:08 EDTPFEBristol-Myers, Pfizer announce enrollment in Phase IV EMANATE trial for Eliquis
Subscribe for More Information
1 | 2 | all recent PFE news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use